ITeos Therapeutics Shares Rise on Positive Data From Lung Cancer …
WEB3 days ago · Resize. By Don Nico Forbes. Shares in iTeos Therapeutics rose after the company reported positive data from a mid-stage study exploring the combination of belrestotug and dostarlimab in the first ...
Buy Rating Affirmed for iTeos Therapeutics Amid Promising Lung …
WEB5 days ago · Eva Fortea Verdejo, an analyst from Wells Fargo, maintained the Buy rating on iTeos Therapeutics (ITOS – Research Report). The associated price target remains the same with $31.00. The ...
TIGIT drug from iTeos shrinks lung tumors in trial - Yahoo Finance
WEB5 days ago · The results, from a mid-stage clinical trial, show that adding iTeos’ drug to an approved GSK immunotherapy shrank lung tumors in roughly twice as many people as GSK’s therapy alone. They have ...
iTeos Announces Clinically Meaningful Objective Response Rate …
WEB5 days ago · Clinically meaningful improvement in the primary endpoint of ORR was observed consistently across each belrestotug + dostarlimab cohort (63.3% Dose A, 65.6% Dose B and 76.7% Dose C compared to 37. ...
iTeos Therapeutics | iTeos Announces Clinically Meaningful …
WEB5 days ago · iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the …
ITeos Therapeutics Shares Rise on Positive Data From Lung
WEB3 days ago · Shares in iTeos Therapeutics rose after the company reported positive data from a mid-stage study exploring the combination of belrestotug and dostarlimab in the first-line treatment of lung ...
iTeos Therapeutics | iTeos Announces 2024 Strategic Priorities and ...
WEBPress Release Details. iTeos Announces 2024 Strategic Priorities and Anticipated Milestones. January 8, 2024. PDF Version. - TIGIT program clinical data readouts anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC.
iTeos Therapeutics | iTeos Therapeutics Announces Late-Breaking …
WEBAug 20, 2024 · WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that interim data from GALAXIES Lung-201, the Phase 2 platform study sponsored by iTeos ...
iTeos Therapeutics, Inc. (ITOS) Latest Stock News & Headlines
WEBGet the latest iTeos Therapeutics, Inc. (ITOS) stock news and headlines to help you in your trading and investing decisions.
iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For …
WEB4 days ago · iTeos Therapeutics' belrestotug shows promising response rates in lung cancer trials, especially when combined with dostarlimab, despite significant safety concerns. Financially, ITOS has over 3 ...